China Medical System Holdings Limited
0867
Κατάταξη σε μετοχές
#4728
Established in 1995 and headquartered in North Point, Hong Kong, China Medical... Established in 1995 and headquartered in North Point, Hong Kong, China Medical System Holdings Limited functions as an investment holding company with a primary focus on the development, marketing, and distribution of a wide array of pharmaceutical products throughout the People's Republic of China. The company's extensive portfolio addresses numerous therapeutic areas. Its cardiovascular offerings include Plendil for hypertension and stable angina, XinHuoSu for acute heart failure, and Imdur for coronary heart disease, chronic heart failure, and myocardial infarction prevention. For mental health and neurological support, it provides Deanxit to treat mild-to-moderate depression and anxiety, along with Parlodel tablets for endocrine and neuro system indications. Digestive and liver conditions are managed with products such as Ursofalk for gallstones and cholestatic liver disease, Salofalk for ulcerative colitis and Crohn's disease, Bioflor for diarrhea, Combizym for dyspepsia, and Ganfule capsules for primary liver cancer, plus MOVICOL for chronic constipation. The company also markets Augentropfen Stulln Mono eye drops for senile macula degeneration and asthenopia, Hirudoid for blunt trauma and superficial phlebitis, Elcatonin injection for osteoporosis, and Lamisil tablets for fungal infections. Respiratory issues are addressed by YiNuoShu, while infectious diseases benefit from DanShenTong capsules (for various infections like acne, tonsillitis, and boils) and YinlianQinggan granules for hepatitis. XiDaKang, a protein hydrolysate oral solution, is also part of its offerings. Beyond its pharmaceutical endeavors, the group is also actively involved in agriculture and livestock operations. China Medical System Holdings Limited operates as a subsidiary of Treasure Sea Limited.
Τιμή μετοχής
$1.31
Κεφαλαιοποίηση
$3.18B
Αλλαγή (1 ημέρα)
-1.63%
Αλλαγή (1 έτος)
-23.03%
Χώρα
HK
Εμπόριο China Medical System Holdings Limited (0867)
Κατηγορία
Healthcare
Έσοδα για την China Medical System Holdings Limited (0867)
Έσοδα τον Jun 2026 TTM: $1.25B
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της China Medical System Holdings Limited, τα τρέχοντα έσοδα της εταιρείας (TTM) είναι $1.25B. Το 2023, η εταιρεία είχε έσοδα $1.13B μείωση σε σύγκριση με τα έσοδα του έτους 2022, τα οποία ήταν $1.33B. Τα έσοδα είναι το συνολικό ποσό που παράγει μια εταιρεία από τις πωλήσεις προϊόντων ή υπηρεσιών. Σε αντίθεση με τα κέρδη, δεν αφαιρούνται έξοδα.
Ιστορικό εσόδων για την China Medical System Holdings Limited από 2006 έως 2026
Έσοδα στο τέλος κάθε έτους
| Έτος | Έσοδα | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $1.25B | 22.48% |
| 2024 | $1.02B | -9.61% |
| 2023 | $1.13B | -14.66% |
| 2022 | $1.33B | 1.13% |
| 2021 | $1.31B | 23.37% |
| 2020 | $1.06B | 21.90% |
| 2019 | $872.23M | 10.42% |
| 2018 | $789.91M | -3.92% |
| 2017 | $822.11M | 16.47% |
| 2016 | $705.87M | 29.00% |
| 2015 | $547.21M | 15.08% |
| 2014 | $475.48M | 31.01% |
| 2013 | $362.92M | 28.63% |
| 2012 | $282.14M | 34.51% |
| 2011 | $209.75M | 57.92% |
| 2010 | $132.82M | 37.69% |
| 2009 | $96.46M | 32.86% |
| 2008 | $72.60M | 40.24% |
| 2007 | $51.77M | 37.69% |
| 2006 | $37.60M | 0.00% |
Έσοδα για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Έσοδα | Διαφορά Εσόδων | Χώρα |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 427.53% |
IN
|
